Drug intelligence / Profile preview

VRP-1023

Development stage: Preclinical
Lead developer: Venus Medicine Research Centre
Administration: Transdermal

Overview

VRP-1023 is a natural product-based therapeutic candidate currently in preclinical development by Venus Medicine Research Centre (VMRC). The drug is formulated as a transdermal patch, a delivery method intended to provide controlled release of the active ingredients through the skin. While VMRC has categorized VRP-1023 within its herbal and natural products pipeline, the specific chemical composition, biological targets, and intended clinical indications remain undisclosed. As of the latest pipeline updates, the formulation and development (F&D) phase has been completed, and the candidate is undergoing active preclinical testing to support future regulatory filings.

Beyond the preview

Go deeper on VRP-1023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRP-1023.

Explore the full profile